Startuprad.io today unveils the Startup AI Concierge, an AI-powered knowledge assistant that transforms how professionals in Europe's startup and innovation ecosystem access insight. Built on over a decade of interviews, analysis, and reporting, the Concierge brings verified, source-cited intelligence directly to founders, investors, and policymakers. https://mma.prnewswire.com/media/2799865/Startuprad_Logo.jpg From Media Platform to Knowledge InfrastructureWhen Startuprad.io launched, it […]

NEW YORK, NY, AL / ACCESS Newswire / October 19, 2025 / WHY: New York, N.Y., October 19, 2025. Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Snap Inc. (NYSE:SNAP) between April 29, 2025 and August 5, 2025, both dates inclusive (the "Class Period"), of the important October 20,

X, AL / ACCESS Newswire / October 19, 2025 / NEW YORK CITY, NY / ACCESS Newswire / October 19, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Rezolve AI plc (NASDAQ: RZLV) resulting from allegations that Rezolve may

Hartgraves & the Adventure in Time! FORT WORTH, TX / ACCESS Newswire / October 19, 2025 / Author Pete Hartgraves is captivating young readers and educators alike with his debut novel, Adventures in Time: My Only Regret – the first book in a thrilling new historical fiction series for middle-grade and young adult readers. The

CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced data regarding two of its investigational influenza candidates will be presented at IDWeek 2025, October 19-22, 2025, in Atlanta, GA. The details of the presentations are as follows: Late-Breaking Oral

NEW YORK CITY, NY / ACCESS Newswire / October 19, 2025 / WHY: New York, N.Y., October 19, 2025. Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Freeport-McMoRan Inc. (NYSE:FCX) resulting from allegations that Freeport may have issued materially misleading business information to

(NASDAQ:REPL), WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced data from a new ad hoc analysis from the IGNYTE phase 2 cohort of RP1 plus nivolumab was presented by Caroline Robert, M.D., Ph.D., at the European

(NasdaqGM:RAPT), SOUTH SAN FRANCISCO, Calif., Oct. 19, 2025 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that the Company plans to report topline data from the Phase 2 clinical trial of RPT904

Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025 GlobeNewswire October 19, 2025 WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced data from a new ad hoc analysis from the IGNYTE

RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU) GlobeNewswire October 19, 2025 SOUTH SAN FRANCISCO, Calif., Oct. 19, 2025 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory